UY27429A1 - MEDICINAL PRODUCT FOR THERAPEUTIC OR PREVENTIVE TREATMENT OF TUBERCULOSIS THAT INCLUDES AN Erythromycin Derivative - Google Patents
MEDICINAL PRODUCT FOR THERAPEUTIC OR PREVENTIVE TREATMENT OF TUBERCULOSIS THAT INCLUDES AN Erythromycin DerivativeInfo
- Publication number
- UY27429A1 UY27429A1 UY27429A UY27429A UY27429A1 UY 27429 A1 UY27429 A1 UY 27429A1 UY 27429 A UY27429 A UY 27429A UY 27429 A UY27429 A UY 27429A UY 27429 A1 UY27429 A1 UY 27429A1
- Authority
- UY
- Uruguay
- Prior art keywords
- tuberculosis
- therapeutic
- substituted
- erythromycin derivative
- memory
- Prior art date
Links
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title abstract 2
- 201000008827 tuberculosis Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000003449 preventive effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Medicamento para tratar y/o prevenir la tuberculosis que comprende un derivado de eritromicina de fórmula (I) y una sal, hidrato y un solvato farmacéuticamente aceptables del mismo, en donde R representa hidrógeno, y otros según la memoria; R1 representa alquilo de C5-12 que puede ser sustituido, y otros según la memoria; R2 representa hidrógeno o un grupo carbamoilo que puede ser sustituido; R3 representa un grupo acilo que puede ser sustituido, y otros segun la memoria; R4 representa un grupo alquilo que puede ser sustituido, y otros según la memoria. Uso de dicho compuesto para fabricar dicho medicamento.Medication for treating and / or preventing tuberculosis comprising an erythromycin derivative of formula (I) and a pharmaceutically acceptable salt, hydrate and solvate thereof, wherein R represents hydrogen, and others according to memory; R1 represents C5-12 alkyl that can be substituted, and others according to memory; R2 represents hydrogen or a carbamoyl group that can be substituted; R3 represents an acyl group that can be substituted, and others according to memory; R4 represents an alkyl group that can be substituted, and others according to memory. Use of said compound to manufacture said medicament.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001268213 | 2001-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27429A1 true UY27429A1 (en) | 2003-10-31 |
Family
ID=19094233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27429A UY27429A1 (en) | 2001-09-05 | 2002-09-03 | MEDICINAL PRODUCT FOR THERAPEUTIC OR PREVENTIVE TREATMENT OF TUBERCULOSIS THAT INCLUDES AN Erythromycin Derivative |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR036587A1 (en) |
| PE (1) | PE20030438A1 (en) |
| UY (1) | UY27429A1 (en) |
| WO (1) | WO2003022289A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005007143A2 (en) * | 2003-07-14 | 2005-01-27 | The Board Of Trustees Of The University Of Illinois | Use of makrolides and ketolides for the treatment of tuberculosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11511112A (en) * | 1995-02-10 | 1999-09-28 | ユニバーシティ・オブ・マサチューセッツ | Delivery of exogenous compounds |
| EP0895999A1 (en) * | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
| CZ20012675A3 (en) * | 1999-01-27 | 2002-04-17 | Pfizer Products Inc. | Ketolide antibiotics |
| AR023264A1 (en) * | 1999-04-08 | 2002-09-04 | Hokuriku Pharmaceutical | ERYTHROMYCIN DERIVATIVES |
| EP1122261A3 (en) * | 2000-01-31 | 2001-09-26 | Pfizer Products Inc. | 13 and 14-membered antibacterial macrolides |
-
2002
- 2002-09-03 WO PCT/JP2002/008922 patent/WO2003022289A1/en not_active Ceased
- 2002-09-03 PE PE2002000836A patent/PE20030438A1/en not_active Application Discontinuation
- 2002-09-03 UY UY27429A patent/UY27429A1/en not_active Application Discontinuation
- 2002-09-04 AR ARP020103336A patent/AR036587A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR036587A1 (en) | 2004-09-22 |
| PE20030438A1 (en) | 2003-07-03 |
| WO2003022289A1 (en) | 2003-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035482A1 (en) | USE OF A CYANOQUINOLINE COMPOUND FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT OR INHIBIT COLONY POLYPS | |
| IT1271495B (en) | PHARMACEUTICAL COMPOSITION CONTAINING 3-2 (DIMETHYLAMINE) ETHYL-N-METHYL-1H-INDOL-5-METHANE SULPHONAMIDE, RELATIVE PROCEDURE FOR PREPARATION AND USE OF THE SAME IN TREATMENT OF MAMMALS | |
| AR029174A1 (en) | DERIVATIVES OF ESPIROOXINDOL, PROCESS FOR PREPARATION, PHARMACEUTICAL FORMULATION, AND USE OF DERIVATIVES IN THE MANUFACTURE OF MEDICINES | |
| ES2295609T3 (en) | TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN. | |
| NO20061506L (en) | Heterocyclic inhibitors of MEK and methods for their use | |
| GEP20053595B (en) | Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment | |
| HN2004000232A (en) | "PIRROLO DERIVATIVES (3,4-C) PIRAZOL ACTIVE AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM." | |
| UY27533A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING OXIBUTININE | |
| BRPI0418026A (en) | phenylalanine derivatives or pharmaceutically acceptable salts thereof, pharmaceutical composition, alpha4 integrin antagonist, and therapeutic or preventative agent for diseases | |
| MX2007006212A (en) | Oral medicament for the modified release of at least one active principle, in multimicrocapsule form. | |
| NO20062905L (en) | Novel hydroxamic acid esters and their pharmaceutical use | |
| SE9901573D0 (en) | New compounds | |
| AR030039A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A SELECTIVE INHIBITOR DRUG OF CYCLOOXYGENASA-2, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT OR PREVENT AFFECTIONS THROUGH CYCLOOXYGENASE-2 AND METHOD TO MAKE SUCH MEDICINAL PRODUCT | |
| NO304113B1 (en) | Crystalline thiagabine hydrochloride monohydrate, pharmaceutical composition comprising it, and use thereof for the manufacture of a medicament | |
| HUP0201284A2 (en) | Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient | |
| FR2850023B1 (en) | DRUGS FOR THE NERVOUS SYSTEM | |
| UY29085A1 (en) | PIRIMIDINE DERIVATIVES 4-SULFONAMID SUBSTITUTED, INTERMEDIATE COMPOUNDS FOR PREPARATION, PREPARATION PROCEDURES, MEDICINAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS | |
| RU2008119454A (en) | MEDICINE FOR PROTECTION OF MOTOR NEURON IN PATIENTS WITH LATERAL AMYOTROPHIC SCLEROSIS | |
| AR018505A1 (en) | ANTIHISTAMINAL PHARMACEUTICAL COMPOSITION WITH AN INHIBITOR OF P-GLYCOPROTEIN AND THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF MEDICINES TO INCREASE THE BIODISPONIBILITY OF SUCH ANTIHISTAMINAL. | |
| ES2196167T3 (en) | PHARMACEUTICAL COMPOSITION CONTAINING PROPIONATE 3- (2,2,2-TRIMETHYL HYDRAZINY) AND GAMMA-BUTIROBETAIN FOR THE TREATMENT OF CARDIOVASCULAR DISEASES. | |
| SE0002476D0 (en) | New compounds | |
| SE0201837D0 (en) | Chemical compounds | |
| UY27429A1 (en) | MEDICINAL PRODUCT FOR THERAPEUTIC OR PREVENTIVE TREATMENT OF TUBERCULOSIS THAT INCLUDES AN Erythromycin Derivative | |
| TW200503709A (en) | Itching treating agent containing piperidine derivative as active ingredient | |
| TR200103144T2 (en) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20101118 |